Pinfang Huang

Cost-effectiveness of atezolizumab plus chemotherapy for advanced non-small-cell lung cancer

Shen Lin, Shaohong Luo, Lixian Zhong et al. · International Journal of Clinical Pharmacy · 2020 · 69 citations

Medicine, Oncology, Pharmacoeconomics +12

Preliminary screening for sarcopenia and related risk factors among the elderly

Li‐Chu Wu, Hsueh-Hui Kao, Hong-Jhe Chen et al. · Medicine · 2021 · 50 citations · Full text

Medicine, Geriatric Medicine, Geriatrics +15

First-Line Treatment With Atezolizumab Plus Nab-Paclitaxel for Advanced Triple-Negative Breast Cancer

Xiuhua Weng, Xiaoting Huang, Hongchao Li et al. · American Journal of Clinical Oncology · 2020 · 42 citations

Pharmacy, Oncology, Pharmacoeconomics +17

Population pharmacokinetics of vancomycin in adult Chinese patients with post-craniotomy meningitis and its application in individualised dosage regimens

Wei-Wei Lin, Wei Wu, Zheng Jiao et al. · European Journal of Clinical Pharmacology · 2015 · 40 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Cost‐Utility Analysis of Pembrolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer With Different PD-L1 Expression Levels

Xiuhua Weng, Shaohong Luo, Shen Lin et al. · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · 2019 · 32 citations · Full text

Pharmacy, Oncology, Pharmacoeconomics +17